In colorectal cancer (CRC), several antigen targets for CAR-T cell therapy are being investigated in clinical trials, including CEA, CD133, C-Met, EGFR, HER2, EpCAM, MUC-1, mesothelin, PSMA, guanylate cyclase-C (GCC), and natural killer group 2 member D ligand (NKG2DL) [222]. Here, CEACAM5 is linked to colorectal cancer.